CCTG at the 2024 EORTC-NCI-AACR Symposium on molecular targets and cancer therapeutics

The 2024 EORTC-NCI-AACR (ENA) Symposium on Molecular Targets and Cancer Therapeutics was held last week in Barcelona and CCTG was there with two IND poster presentations. The ENA symposium is a leading event for drug development and translational research. It focuses on preclinical, and phase I studies and provides a platform for scientific discussions on the latest advancements in targets and therapeutics. 

IND241 - A liquid-biopsy informed platform trial to evaluate treatment in CDK4/6-inhibitor resistant ER+/HER2- metastatic breast cancer

Conclusion: To date, 13 patients have been enrolled into 3 cohorts. IND.241 employs a biomarker-driven platform study design approach to the evaluation of CDKi resistant ER+/HER2- MBC, using non-invasive ctDNA tumor genotyping to select patients for biomarker-driven substudies and define the ctDNA landscape across 1st, 2nd and 3L treatments. Safety, efficacy and correlative evaluation is ongoing.Additional substudies are being developed.

IND241 employs a biomarker-driven platform study design approach to the evaluation of CDKi resistant ER+/HER2- MBC, using non-invasive ctDNA tumor genotyping to select patients for biomarker-driven substudies and define the ctDNA landscape across 1st, 2nd and 3L treatments. The trial is supported by three peer reviewed grants and has enabled the launch of multiple biomarker informed substudies, with two in progress, and another being submitted for approvals with multiple others in development.

See the full poster > 

IND243 - A phase II study of RP-6306 in patients with advanced cancer

Conclusion: To date 28 patients have been enrolled into 6 cohorts. A total of 76 cycles have been administered. Toxicities of LUN and GEM are overlapping. Rash related to LUN appears early, is distinct from GEM and is manageable with dose modification. Clinical activity with minor responses seen in 3 patients with HGSOC (2 patients platinum refractory; PPR-HGSOC). New cohort opening for PPR-HGSOC with lunresertib + camonsertib. Correlative analyses are ongoing.

To date 28 patients have been enrolled into six cohorts testing a combination of lunresertib (LUN) and gemcitabine (GEM). A total of 76 cycles have been administered. Rash related to LUN appears early, is distinct from GEM and is manageable with dose modification. Clinical activity with minor responses seen in three patients with High Grade Serous Ovarian Carcinoma (two patients platinum refractory; PPR-HGSOC). A new cohort is opening shortly for patients with PPR-HGSOC testing lunresertib and camonsertib. Correlative analyses are ongoing.

See the full poster >